Studie Mirati 516-005 / Sapphire

Mirati 516-005 / Sapphire

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy Z-Nr.: 406

NCT03906071

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Unbekannt / Unbekannt

Chemo,Zielgerichtet